Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK715m

    Last close

    SEK13.80

    ▲ −0.30 (−2.13%)

    VolitionRx

    MCap

    USD56m

    Last close

    USD0.60

    ▲ 0.00 (−0.66%)

    Portobello SpA

    MCap

    EUR16m

    Last close

    EUR2.90

    ▲ 0.52 (21.85%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Chimeric Therapeutics (ASX: CHM)

Last close As at 04/11/2024

0.04

— 0.00 (0.00%)

Market capitalisation

22m

Latest Insights

Healthcare | Update

Chimeric Therapeutics — Acquiring an exciting new NK cell technology

Healthcare | Update

Chimeric Therapeutics — Acquiring a promising first-in-class CAR T asset

Healthcare | Initiation

Chimeric Therapeutics — Scorpion venom CAR-T stalking GBM
Visit Website

Balance Sheet

Forecast net cash (A$m)

8.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (47.4) (45.9) (66.7)
Relative (46.7) (45.2) (67.3)
52 week high/low A$0.2/A$0.0

Financials

Edison Investment Research is terminating coverage on Chimeric Therapeutics (CHM). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (c) P/E (x) P/CF (x)
2020A 0.0 (0.1) (0.1) (6200.80) N/A N/A
2021A 0.0 (14.8) (14.9) (8.16) N/A N/A
2022E 0.0 (14.0) (14.0) (4.19) N/A N/A
2023E 0.0 (14.5) (14.5) (4.32) N/A N/A

Research

Update

Healthcare

Chimeric Therapeutics — Acquiring a promising first-in-class CAR T asset

Initiation

Healthcare

Chimeric Therapeutics — Scorpion venom CAR-T stalking GBM

Healthcare

Update

Chimeric Therapeutics — Acquiring an exciting new NK cell technology

Thematics

View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free